<DOC>
	<DOCNO>NCT01154439</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , mitoxantrone hydrochloride , cytarabine , etoposide , idarubicin , work different way stop growth cancer cell , either kill cell stop dividing . Everolimus may stop growth cancer cell block enzymes need cell growth block blood flow cancer . Giving everolimus together combination chemotherapy may kill cancer cell . PURPOSE : This phase I trial study side effect best dose everolimus give together mitoxantrone hydrochloride , cytarabine , etoposide , idarubicin treat old patient newly diagnose acute myeloid leukemia .</brief_summary>
	<brief_title>Everolimus MICE-regimen Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum-tolerated dose everolimus combination standard remission-induction therapy comprise mitoxantrone hydrochloride , cytarabine , etoposide ( MICE-regimen ) follow consolidation therapy comprise idarubicin , cytarabine , etoposide old patient newly diagnose acute myeloid leukemia . Secondary - To determine safety profile regimen patient . - To determine anti-leukemic activity ( complete remission rate [ complete remission complete remission incomplete blood count recovery ] ) follow one two induction course . OUTLINE : This multicenter , dose-escalation study everolimus . - Standard remission-induction therapy : Patients receive mitoxantrone hydrochloride IV 30 minute day 1 , 3 , 5 ; cytarabine IV continuously day 1-7 ; etoposide IV 1 hour day 1-3 ; oral everolimus day day 1-21 . Patients partial remission ( PR ) receive second induction course , begin 7-17 day completion induction course 1 . Patients complete remission complete remission incomplete blood count recovery ( CR/CRi ) induction therapy proceed consolidation therapy ; patient fail achieve PR induction course 1 CR/CRi induction course 2 remove study . - Consolidation therapy : Beginning within 3 week CR/CRi documentation , patient receive idarubicin IV 30 minute day 1 , 3 , 5 ; cytarabine IV continuously day 1-5 ; etoposide IV 1 hour day 1-3 ; oral everolimus day day 1-10 . Patients may receive another course consolidation therapy , begin least 4 week initiation consolidation therapy course 1 . After completion study treatment , patient follow month 1 year , every 3 month 1 year , periodically thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute myeloid leukemia ( AML ) ( unequivocal ) accord WHO diagnostic criterion ( least 20 % blast bone marrow ) , FAB classification M3 ( acute promyelocytic leukemia ) , document bone marrow aspiration ( biopsy case dry tap ) Previously untreated primary secondary AML ( include AML follow antecedent myelodysplasia ) No blast transformation chronic myeloid leukemia myeloproliferative disorder No active CNS leukemia PATIENT CHARACTERISTICS : WHO performance status 02 Total serum bilirubin &lt; 2 time upper limit normal ( ULN ) Serum creatinine &lt; 2 time ULN ALT/AST ≤ 3 time ULN ( unless due organ leukemic involvement ) LVEF ≥ 50 % echocardiogram No concurrent active malignancy No active uncontrolled infection No known active hepatitis B C HIV positivity No active heart disease include myocardial infarction within past 3 month , symptomatic coronary artery disease , cardiac arrhythmia control medication , uncontrolled congestive heart failure No medical condition , opinion investigator , place patient unacceptably high risk toxicity No know condition ( e.g. , familial , sociological , geographical ) behavior ( include drug dependence abuse , psychological psychiatric illness ) , opinion investigator , would make patient poor candidate trial No know hypersensitivity everolimus , rapamycins ( e.g. , sirolimus temsirolimus ) , excipients PRIOR CONCURRENT THERAPY : No prior standard investigational chemotherapy acute myeloid leukemia myelodysplasia ( include everolimus mTOR inhibitor ) Prior hydroxyurea allow ( maximum 14 day ) control peripheral blood leukemic cell count No prior enrollment trial No concurrent antileukemia agent , investigational agent , biological agent</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>